PT99622A - Processo de preparacao de proteinas substancialmente purificadas derivadas de orgaos de embriao de mamifero e de composicoes farmaceuticas - Google Patents

Processo de preparacao de proteinas substancialmente purificadas derivadas de orgaos de embriao de mamifero e de composicoes farmaceuticas Download PDF

Info

Publication number: PT99622A
Authority: PT; Portugal
Prior art keywords: cells; organs; substantially purified; molecular weight; supernatant
Prior art date: 1990-11-28

Application number

PT99622A

Other languages

English (en)

Portuguese (pt)

Original Assignee

Eytan R Barnea

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-11-28

Filing date

1991-11-27

Publication date

1992-10-30

1991-11-27 Application filed by Eytan R Barnea filed Critical Eytan R Barnea

1992-10-30 Publication of PT99622A publication Critical patent/PT99622A/pt

Links

108090000623 proteins and genes Proteins 0.000 title claims description 46
102000004169 proteins and genes Human genes 0.000 title claims description 45
238000000034 method Methods 0.000 title claims description 43
210000001161 mammalian embryo Anatomy 0.000 title claims description 32
239000008194 pharmaceutical composition Substances 0.000 title claims 4
241000124008 Mammalia Species 0.000 title description 3
210000004027 cell Anatomy 0.000 claims description 65
239000003795 chemical substances by application Substances 0.000 claims description 62
239000000284 extract Substances 0.000 claims description 48
206010028980 Neoplasm Diseases 0.000 claims description 32
230000001028 anti-proliverative effect Effects 0.000 claims description 26
230000028327 secretion Effects 0.000 claims description 26
101150102561 GPA1 gene Proteins 0.000 claims description 24
230000003169 placental effect Effects 0.000 claims description 23
238000011161 development Methods 0.000 claims description 21
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 claims description 21
201000011510 cancer Diseases 0.000 claims description 20
238000004128 high performance liquid chromatography Methods 0.000 claims description 18
210000000056 organ Anatomy 0.000 claims description 18
238000002360 preparation method Methods 0.000 claims description 18
239000006228 supernatant Substances 0.000 claims description 17
230000008569 process Effects 0.000 claims description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 12
230000001537 neural effect Effects 0.000 claims description 12
238000011282 treatment Methods 0.000 claims description 12
230000035558 fertility Effects 0.000 claims description 10
239000000463 material Substances 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 9
239000000047 product Substances 0.000 claims description 9
230000002401 inhibitory effect Effects 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 8
210000001835 viscera Anatomy 0.000 claims description 8
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 7
230000009702 cancer cell proliferation Effects 0.000 claims description 6
210000000472 morula Anatomy 0.000 claims description 6
238000002264 polyacrylamide gel electrophoresis Methods 0.000 claims description 6
238000000605 extraction Methods 0.000 claims description 5
238000000527 sonication Methods 0.000 claims description 5
238000005119 centrifugation Methods 0.000 claims description 4
210000002308 embryonic cell Anatomy 0.000 claims description 4
239000002953 phosphate buffered saline Substances 0.000 claims description 4
241000826760 Barnea Species 0.000 claims description 3
229960004407 chorionic gonadotrophin Drugs 0.000 claims description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 3
239000000243 solution Substances 0.000 claims description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 9
230000009278 visceral effect Effects 0.000 claims 5
239000012149 elution buffer Substances 0.000 claims 3
210000001109 blastomere Anatomy 0.000 claims 1
210000004962 mammalian cell Anatomy 0.000 claims 1
238000002604 ultrasonography Methods 0.000 claims 1
230000002062 proliferating effect Effects 0.000 description 30
108010062540 Chorionic Gonadotropin Proteins 0.000 description 27
102000011022 Chorionic Gonadotropin Human genes 0.000 description 27
230000000694 effects Effects 0.000 description 27
229940084986 human chorionic gonadotropin Drugs 0.000 description 27
230000018109 developmental process Effects 0.000 description 20
210000001519 tissue Anatomy 0.000 description 20
241000699670 Mus sp. Species 0.000 description 18
210000002257 embryonic structure Anatomy 0.000 description 16
230000035935 pregnancy Effects 0.000 description 16
239000000872 buffer Substances 0.000 description 13
210000002993 trophoblast Anatomy 0.000 description 13
238000002474 experimental method Methods 0.000 description 11
210000000278 spinal cord Anatomy 0.000 description 11
210000002459 blastocyst Anatomy 0.000 description 10
239000012634 fragment Substances 0.000 description 10
238000004458 analytical method Methods 0.000 description 9
230000004663 cell proliferation Effects 0.000 description 9
230000035755 proliferation Effects 0.000 description 9
230000004083 survival effect Effects 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
101150077323 GPA2 gene Proteins 0.000 description 8
239000000499 gel Substances 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
230000000670 limiting effect Effects 0.000 description 7
210000002826 placenta Anatomy 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 6
239000003433 contraceptive agent Substances 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
102000007299 Amphiregulin Human genes 0.000 description 5
108010033760 Amphiregulin Proteins 0.000 description 5
201000008808 Fibrosarcoma Diseases 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
239000000427 antigen Substances 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
230000002254 contraceptive effect Effects 0.000 description 5
230000012010 growth Effects 0.000 description 5
210000003734 kidney Anatomy 0.000 description 5
210000004072 lung Anatomy 0.000 description 5
230000008774 maternal effect Effects 0.000 description 5
239000000523 sample Substances 0.000 description 5
241000894007 species Species 0.000 description 5
102000008186 Collagen Human genes 0.000 description 4
108010035532 Collagen Proteins 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
241000699660 Mus musculus Species 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
239000012298 atmosphere Substances 0.000 description 4
229920001436 collagen Polymers 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000001605 fetal effect Effects 0.000 description 4
239000007789 gas Substances 0.000 description 4
230000002163 immunogen Effects 0.000 description 4
238000002513 implantation Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
238000011580 nude mouse model Methods 0.000 description 4
230000002572 peristaltic effect Effects 0.000 description 4
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
241000283690 Bos taurus Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010061216 Infarction Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
102000004576 Placental Lactogen Human genes 0.000 description 3
108010003044 Placental Lactogen Proteins 0.000 description 3
239000000381 Placental Lactogen Substances 0.000 description 3
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
239000002253 acid Substances 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
210000000481 breast Anatomy 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000013020 embryo development Effects 0.000 description 3
230000002357 endometrial effect Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
208000000509 infertility Diseases 0.000 description 3
230000036512 infertility Effects 0.000 description 3
231100000535 infertility Toxicity 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
238000011275 oncology therapy Methods 0.000 description 3
230000002611 ovarian Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
231100000167 toxic agent Toxicity 0.000 description 3
239000003440 toxic substance Substances 0.000 description 3
239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 2
102400001368 Epidermal growth factor Human genes 0.000 description 2
101800003838 Epidermal growth factor Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
241001467552 Mycobacterium bovis BCG Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
239000004365 Protease Substances 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
210000004100 adrenal gland Anatomy 0.000 description 2
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000032823 cell division Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
108010032970 decidua inhibitory factor Proteins 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
229940116977 epidermal growth factor Drugs 0.000 description 2
208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 description 2
210000003238 esophagus Anatomy 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
210000003754 fetus Anatomy 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
230000007574 infarction Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000002609 medium Substances 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
210000003101 oviduct Anatomy 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
238000005303 weighing Methods 0.000 description 2
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
206010000234 Abortion spontaneous Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
206010004272 Benign hydatidiform mole Diseases 0.000 description 1
206010060999 Benign neoplasm Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
102000012406 Carcinoembryonic Antigen Human genes 0.000 description 1
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000001951 Fetal Death Diseases 0.000 description 1
241001290006 Fissurella Species 0.000 description 1
206010055690 Foetal death Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
208000006937 Hydatidiform mole Diseases 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
208000014767 Myeloproliferative disease Diseases 0.000 description 1
208000003019 Neurofibromatosis 1 Diseases 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
208000031845 Pernicious anaemia Diseases 0.000 description 1
101710158668 Placental protein Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
208000006994 Precancerous Conditions Diseases 0.000 description 1
102000008217 Pregnancy Proteins Human genes 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
102000013529 alpha-Fetoproteins Human genes 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
201000003163 breast adenoma Diseases 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
230000004087 circulation Effects 0.000 description 1
208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
230000002729 effect on secretion Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
208000016253 exhaustion Diseases 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
231100000479 fetal death Toxicity 0.000 description 1
230000004907 flux Effects 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
239000003292 glue Substances 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000003821 menstrual periods Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
230000032696 parturition Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
210000005059 placental tissue Anatomy 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
238000005086 pumping Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
208000000995 spontaneous abortion Diseases 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000007801 sublethal irradiation Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
210000000251 trophoblastic cell Anatomy 0.000 description 1
230000001573 trophoblastic effect Effects 0.000 description 1
208000029387 trophoblastic neoplasm Diseases 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
230000008347 uteroplacental blood flow Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000036266 weeks of gestation Effects 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Toxicology (AREA)
Reproductive Health (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PT99622A 1990-11-28 1991-11-27 Processo de preparacao de proteinas substancialmente purificadas derivadas de orgaos de embriao de mamifero e de composicoes farmaceuticas PT99622A (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL96499A IL96499A0 (en)	1990-11-28	1990-11-28	Anticancer protein-like extract

Publications (1)

Publication Number	Publication Date
PT99622A true PT99622A (pt)	1992-10-30

Family

ID=11061807

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT99622A PT99622A (pt)	1990-11-28	1991-11-27	Processo de preparacao de proteinas substancialmente purificadas derivadas de orgaos de embriao de mamifero e de composicoes farmaceuticas

Country Status (9)

Country	Link
EP (1)	EP0512102A4 (fr)
JP (1)	JPH05508419A (fr)
AU (1)	AU9085491A (fr)
CA (1)	CA2074476A1 (fr)
IE (1)	IE914128A1 (fr)
IL (1)	IL96499A0 (fr)
PT (1)	PT99622A (fr)
WO (1)	WO1992009294A1 (fr)
ZA (1)	ZA919361B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4400640A1 (de) *	1994-01-12	1995-07-13	Eftag Entstaubung Foerdertech	Verwendung von, Mittel mit und Verfahren zur Herstellung eines Arzneimittels mit Embryonalgewebe
RU2065307C1 (ru) *	1994-12-13	1996-08-20	Александр Васильевич Тихонов	Способ лечения первичного рака печени и набор для лечения первичного рака печени
EP1652529A3 (fr) *	1998-07-02	2007-11-21	Envision Biomedical Consulting	Protéines et peptides antiprolifératifs et antiviraux
ATE383866T1 (de) *	1998-07-02	2008-02-15	Envision Biomedical Consulting	Antiproliferative und antivirale proteine und peptide
US7723290B2 (en)	2004-10-22	2010-05-25	Bioincept, Llc	Compositions and methods for modulating the immune system
US7495071B2 (en)	2004-07-14	2009-02-24	Biospectrum, Inc.	Antiproliferative peptides and antibodies for their detection
EP2680872B1 (fr)	2011-03-02	2018-08-15	BioIncept LLC	Compositions et procédés pour traiter des lésions intracellulaires
EP3341739A4 (fr)	2015-08-28	2019-07-10	BioIncept LLC	Peptides mutants et procédés de traitement de sujets les employant
CA2996874A1 (fr)	2015-08-28	2017-03-09	Bioincept, Llc	Compositions et methodes pour le traitement d'une lesion neurologique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2451193A1 (fr) *	1979-03-13	1980-10-10	Brunel Henri	Procede pour le traitement du cancer et preparation des produits employes pour ce traitement
CH671516A5 (fr) *	1986-09-16	1989-09-15	Amcis Ag

1990
- 1990-11-28 IL IL96499A patent/IL96499A0/xx unknown
1991
- 1991-10-31 AU AU90854/91A patent/AU9085491A/en not_active Abandoned
- 1991-10-31 WO PCT/US1991/008046 patent/WO1992009294A1/fr not_active Ceased
- 1991-10-31 CA CA002074476A patent/CA2074476A1/fr not_active Abandoned
- 1991-10-31 JP JP4501045A patent/JPH05508419A/ja active Pending
- 1991-10-31 EP EP9292900487A patent/EP0512102A4/en not_active Withdrawn
- 1991-11-27 PT PT99622A patent/PT99622A/pt not_active Application Discontinuation
- 1991-11-27 ZA ZA919361A patent/ZA919361B/xx unknown
- 1991-11-27 IE IE412891A patent/IE914128A1/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
IE914128A1 (en)	1992-06-03
IL96499A0 (en)	1991-08-16
CA2074476A1 (fr)	1992-05-29
ZA919361B (en)	1992-09-30
JPH05508419A (ja)	1993-11-25
WO1992009294A1 (fr)	1992-06-11
EP0512102A4 (en)	1994-10-05
AU9085491A (en)	1992-06-25
EP0512102A1 (fr)	1992-11-11

Publication	Publication Date	Title
Magnaldo et al.	1998	Galectin-7, a marker of all types of stratified epithelia
US5648340A (en)	1997-07-15	Gestational agents for controlling cell proliferation
KR101806370B1 (ko)	2017-12-07	보다 높은 탄수화물 항원 밀도 및 신규한 사포닌 애쥬번트를 갖는 백신
BR0108566A (pt)	2002-11-19	Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico
MacLennan et al.	1986	Ripening of the human cervix and induction of labor with intracervical purified porcine relaxin
EA030000B1 (ru)	2018-06-29	Способ стимуляции развития зрелого ооцита
PT99622A (pt)	1992-10-30	Processo de preparacao de proteinas substancialmente purificadas derivadas de orgaos de embriao de mamifero e de composicoes farmaceuticas
Stewart et al.	1994	Identification of the horse epidermal growth factor (EGF) coding sequence and its use in monitoring EGF gene expression in the endometrium of the pregnant mare
Joshi et al.	2003	Postnatal development and testosterone dependence of a rat epididymal protein identified by neonatal tolerization
Gage et al.	1988	Human amnion membrane matrix as a substratum for axonal regeneration in the central nervous system
Mattila et al.	1988	Urinary epidermal growth factor concentrations in various human malignancies
TW201603821A (zh)	2016-02-01	免疫性ｌｈｒｈ組成物及其於豬隻之應用
JP4384054B2 (ja)	2009-12-16	新生物形成の処置のための増殖調節因子及びホルモンの組合せ
JPH03503403A (ja)	1991-08-01	生物学的に活性な分子
RU2607379C2 (ru)	2017-01-10	Раковый антиген
TW202444690A (zh)	2024-11-16	萘環類小分子化合物的用途
US6790457B1 (en)	2004-09-14	Compositions and methods for reducing or preventing fertilization in fish and birds
KR100298858B1 (ko)	2001-11-14	포유류수컷의불임치료를위한조성물
EP1140151A2 (fr)	2001-10-10	Compositions et procedes pour reduire ou prevenir la fertilisation chez des poissons et des oiseaux
JP6725942B2 (ja)	2020-07-22	卵胞刺激ホルモン分泌促進剤
EP4582093A1 (fr)	2025-07-09	Composition améliorant les chances de conception de ruminants
Allen et al.	1935	The estrous cycles of mice during growth of spontaneous mammary tumors and the effects of ovarian follicular and anterior pituitary hormones
JPH07502755A (ja)	1995-03-23	胎盤タンパク質１４を使用する，再発性流産の治療法と繁殖補助技術の効能の改善法
Mehta et al.	1999	A mannose-binding glycoprotein found in the 4 day post coital rat uterus is involved in pregnancy
AU2019200941B2 (en)	2021-02-25	Anti-GnRH vaccine

Legal Events

Date	Code	Title	Description
1992-10-30	BB1A	Laying open of patent application	Effective date: 19920617
1999-05-31	FC3A	Refusal	Effective date: 19990205